The vast majority of the active ingredients used in pharmaceutical products consumed in the West are manufactured in China. Although there have been fears that the lockdown imposed by Chinese authorities at and around the time of the Lunar New Year would lead to bottlenecks in production and shortages later in the year, these worries are now being downplayed. Many factories returned to work immediately after the extended holiday period and have been ramping up production to meet demand. The high levels of inventory which exist in the pharma supply chain (typically 180 days plus) should mean that the disruption is kept to a minimum.
Enter your details below and we will email you a copy of the whitepaper:
